Antiphospholipid antibodies and the risk of severe and non‐severe pre‐eclampsia: the NOHA case‐control study
Antiphospholipid antibodies and the risk of severe and non‐severe pre‐eclampsia: the NOHA case‐control study
复制标题
DOI：
10.1111/jth.13257
复制
发表时间：
2016-04
影响因子：
10.4
通讯作者：
T. Marchetti;P. Moerloose;Jean-Christophe Gris
中科院分区：
文献类型：
--
作者：
T. Marchetti;P. Moerloose;Jean-Christophe Gris
摘要我们研究了有先兆子痫史的妇女中抗磷脂抗体(APL)的发生率。检测血浆中经典的β和其他“新”抗体，如抗APL 2GP1结构域Ig G。重度子痫前期与非重度子痫前期不同，主要与抗β2GP1Ig G有关。特异性抗β2GP1抗体与其他APLIg G试验相关。
Essentials We studied the incidence of antiphospholipid antibodies (aPLs) in women with previous pre‐eclampsia. Plasma was tested for classical aPLs and other ‘new’ antibodies such as antiβ2GP1 domain I IgG. Severe pre‐eclampsia is distinct from non‐severe and is mainly associated with antiβ2GP1 IgG. Specific antiβ2GP1 antibodies IgG against domain I correlate with other aPL IgG tests.